Insutrend 30/70 40IU/ml Injection is a premixed insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. This combination provides both intermediate-acting and short-acting insulin components, allowing for improved glycemic control by addressing both basal and prandial insulin requirements. The intermediate-acting insulin isophane component ensures a sustained release of insulin, helping to maintain basal insulin levels, while the human insulin component facilitates rapid onset of action to control postprandial glucose spikes. Insutrend 30/70 is indicated for patients with type 1 diabetes mellitus and those with type 2 diabetes mellitus who require insulin to achieve optimal blood glucose control. The injection should be administered subcutaneously, with dosage and timing individualized based on patient needs, blood glucose monitoring, and physician guidance. Proper rotation of injection sites is recommended to prevent lipodystrophy. Patients should be educated on recognizing and managing hypoglycemia, a potential adverse effect. Insutrend 30/70 should be stored under recommended conditions to maintain potency. This insulin combination offers a convenient and effective option for patients requiring both basal and prandial insulin coverage in a single injection.